5'-CpG island promoter hypermethylation of the CAV-1 gene in breast cancer patients of Kashmir

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 1, 2012, Pages 371-375

  Syeed, Nidda ^a,b   Hussain, Firdous ^a   Husain, Syed Akhtar ^b   Siddiqi, Mushtaq A ^a  

^a SHER I KASHMIR INSTITUTE OF MEDICAL SCIENCES   (India)

^b JAMIA MILLIA ISLAMIA CENTRAL UNIVERSITY   (India)

Author keywords

Breast cancer; CAV 1; Kasmir; Promoter hypermethylation; rt PCR

Indexed keywords

CAV1 PROTEIN, HUMAN; CAVEOLIN 1; DNA; MESSENGER RNA;

ARTICLE; BREAST TUMOR; CANCER STAGING; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; INDIA; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGION; RANDOMIZED CONTROLLED TRIAL;

BREAST NEOPLASMS; CAVEOLIN 1; COHORT STUDIES; CPG ISLANDS; DNA METHYLATION; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDIA; MIDDLE AGED; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS, GENETIC; RNA, MESSENGER;

EID: 84864884258     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.1.371     Document Type: Article

References (29)

1. Ahuja N, Li Q, Mohan AL, Baylin SB, Issa JP (1998). Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res, 58, 5489-94.
2. Baylin, Herman, Graff, et al (1998). Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res, 72, 141-96.
3. Chen, ST, Lin SY, et al (2004). Mutational, epigenetic and expressional analyses of caveolins-1 gene in breast cancers.Int J Mol Med, 14, 577-82.
4. Engelman JA, Zhang XL, Lisanti MP (1999). Sequence and detailed organization of the human caveolin-1 and -2 genes located near the D7S522 locus (7q31.1). Methylation of a CpG island in the 50promoter region of the caveolin-1 gene in human breast cancer cell lines. FEBS Lett, 448, 221-30.
5. Ferguson DJ, Anderson TJ (1981). Morphological evaluation of cell turnover in relation to the menstrual cycle in the "resting" human breast. Br J Cancer, 44, 177-81.
6. Goetz, JG, P Lajoie, et al (2008). Caveolin-1 in tumor progression: the good, the bad and the ugly. Cancer Metastasis Rev, 27, 715-35.
7. Han SY, Druck T, Huebner K (2003). Candidate tumor suppressor genes at FRA7G are coamplified with MET and do not suppress malignancy in a gastric cancer. Genomics, 81, 105-7.
8. Hanahan D, Weinberg RA (2000). The hallmarks of cancer. Cell, 100, 57-70.
9. Hayashi K, Matsuda S, Machida K, et al (2001). Invasion activating caveolin-1 mutation in human scirrhous breast cancers. Cancer Res, 61, 2361-4.
10. Hnasko R, Lisanti MP (2003). The biology of caveolae: lessons from caveolin knockout mice and implications for human disease. Mol Interv, 3, 445-?.
11. Huang CS, Chem HD, Chang KJ, et al (1999). Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP 17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res, 59, 4870-5.
12. Huilt, T Bash, ONE AUTHOR, et al (2000). The cyclin D1 gene is transcriptionally repressed by caveolins-1. J Biol Chem, 275, 21203-9.
13. Issa JP, Vertino PM, Wu J, et al (1993). Increased cytosine DNA-methyltransferase activity during colon cancer progression. J Natl Cancer Inst, 85, 1235-40.
14. Jones PA, Laird PW. (1999) Cancer epigenetics comes of age. Nat Genet, 21, 163-7.
15. Koleske, D Baltimore, et al (1995). Reduction of caveolin and caveolae in oncogenically transformed cells. Proc Natl Acad Sci, 92, 1381-5.
16. Lee SW, Reimer CL, Oh P, Campbell DB, Schnitzer JE (1998) Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene, 16, 1391-7.
17. Longacre TA, Bartow SA (1986). A correlative morphologic study of human breast and endometrium in the menstrual cycle. Am J Surg Pathol, 10, 382-93.
18. Meyer JS (1977). Cell proliferation in normal human breast ducts, fibroadenomas, and other ductal hyperplasias measured by nuclear labeling with tritiated thymidine. Effects of menstrual phase, age, and oral contraceptive hormones. Hum Pathol, 8, 67-81.
19. Nidda Syeed, Syed Akhtar Hussain, Safiya Abdullah, et al (2010) . Caveolin-1 Promotes Mammary Tumorigenesis: Mutational Profile of the Kashmiri Population. Asian Pacific J Cancer Prev, 11, 1-6.
20. Nishizuka S, Tamura G, Terashima M, Satodate R (1997). Commonly deleted region on the long armof chromosome 7 in differentiated adenocarcinoma of the stomach. Br J Cancer, 76, 1567-71.
21. Okamoto T, Schlegel A, Scherer PE, Lisanti MP. (1998).Caveolins,a family of scaffolding proteins for organizing 'preassembled signaling complexes' at the plasma membrane. J Biol Chem, 273, 5419-22.
22. Park, SS, Kim JE, et al (2005). Caveolin-1 is down-regulated and inversely correlated with HER2 and EGFR expression status in invasive ductal carcinoma of the breast.Histopathology, 47, 625-30.
23. Parkin DM, Bray F, Ferlay J, Pisani P (2005).Global cancer statistics,2002. CA Cancer J Clin, 55, 74-108.
24. Pinilla, SM, Honrado E, et al (2006).Caveolin-1 expression is associated with a basal like phenotype in sporadic and hereditary breast cancer. Breast cancer Res Treat, 99, 85-90.
25. Razani B, Schlegel A, Lisanti MP (2000).Caveolin proteins in signaling, oncogenic transformation and muscular dystrophy. J Cell Sci, 113, 2103-9
26. Razani, B, XL Zhang, et al (2001)Caveolin-1 regulates transforming growth factor (TGF) beta/SMAD signaling through an interaction with the TGF-beta type I receptor. J Biol Chem, 276, 6727-38.
27. Sipetić S, Petrović V, Milić Z, Vlajinac H (2004). Breast cancer incidence among women of Branicevo region in the period 1991-2000. Med Pregl, 57, 467-72.
28. Williams TM, Lisanti MP (2005). Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol, 288, 494-506.
29. Williams, TM, Cheung MW (2003). Loss of caveolins-1 gene expression accelerates the development of dysplastic mammary lesions in tumor prone transgenic mice. Mol Biol Cell, 14, 1027-42.